Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review [ID537]: final appraisal determination document
This page was last updated: 03 September 2015
This page was last updated: 03 September 2015